NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target […]
NeuroPace (NASDAQ:NPCE – Free Report) had its price objective hoisted by Cantor Fitzgerald from $16.00 to $18.00 in a report issued on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock. A number of other analysts have also recently commented on the stock. Lake Street Capital reiterated a buy rating […]
EAM Investors LLC purchased a new position in NeuroPace, Inc. (NASDAQ:NPCE – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 141,616 shares of the company’s stock, valued at approximately $1,378,000. EAM Investors LLC owned about 0.54% of NeuroPace […]
EAM Investors LLC purchased a new stake in NeuroPace, Inc. (NASDAQ:NPCE – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 141,616 shares of the company’s stock, valued at approximately $1,378,000. A number of other institutional investors also recently modified […]
NeuroPace (NASDAQ:NPCE – Get Free Report) had its target price hoisted by Wells Fargo & Company from $9.00 to $16.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 1.14% from the company’s […]